Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00590) | |||||
---|---|---|---|---|---|
Name |
Rifabutin
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Ansamycin; Mycobutin; Rifabutine; Ansatipine; Ansatipin; Alfacid; 72559-06-9; LM-427; 4-N-isobutylspiropiperidylrifamycin S; Rifabutine [French]; Rifabutinum [Latin]; Rifabutina [Spanish]; Antibiotic LM 427; LM 427; 1,4-Dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin XIV; 4-Deoxo-3,4-(2-spiro(N-isobutyl-4-piperidyl)-2,5-dihydro-1H-imidazo)-rifamycin S; NCGC00090762-01; DSSTox_CID_10773; DSSTox_RID_79103; DSSTox_GSID_33960; CAS-72559-06-9; Rifabutina; Rifabutinum; Ansamicin; Assatipin; HSDB 3577; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6,18,20-trihydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethyl-5,10,26-trioxo-3,5,9,10-tetrahydrospiro[9,4-(epoxypentadeca[1,11,13]trienoimino)furo[2',3':7,8]naphtho[1,2-d]imidazole-2,4'-piperidin; DRG-0085; BRN 3584778; Prestwick2_001109; SCHEMBL36043; MLS001061256; HMS1571M20; HMS3259D12; HMS3715M20; Tox21_111012; Tox21_200758; MFCD00866816; Rifabutin [USAN:USP:INN:BAN:JAN]; ZINC169621215; CCG-221109; DB00615; Rifamycin XIV, 1,4-dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxo-; NCGC00090762-02; NCGC00258312-01; (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-6-16,18,20-Tetrahydroxy-1'-isobutyl-14-methoxy-7,9,15,17,19,21,25-heptamethylspiro(9,4-(epoxypentadeca(1,11,13)trienimino)-2H-furo(2',3':7,8)naphth(1,2-d)imidazole-2,4'-piperidine)-5,10,26(3H,9H)-trione,16-acetate; SMR001227203; C07235; AB01209745-01; AB01274733-01; AB01274733_02; 559R069; Q1135705; (trihydroxy-1'-isobutyl-methoxy-heptamethyl-trioxo-spiro[[?]-4,4'-piperidine]yl) acetate; (7S,11S,12R,13S,14R,15R,16R,17S,18S)-2,15,17-trihydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23,32-trioxo-8,33-dioxa-24,27,29-triazaspiro[pentacyclo[23.6.1.1^{4,7}.0^{5,31}.0^{26,30}]tritriacontane-28,4'-piperidin]-1,3,5(31),9,19,21,25,29-octaen-13-yl acetate; Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione, 16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptamethyl-1'-(2-methylpropyl)-, (9S,12E,14S,15R,16S,17R,18R,19R,20S,21S,22E,24Z)-
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Pulmonary tuberculosis | ICD-11: 1B10 | [1] | ||
PubChem CID | |||||
Formula |
C46H62N4O11
|
||||
Canonical SMILES |
C[C@H]1/C=C/C=C(\\C(=O)N=C2C(=C3C(=C4C2=NC5(N4)CCN(CC5)CC(C)C)C6=C(C(=C3O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)O)/C
|
||||
InChI |
1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,48,52-55H,16-19,21H2,1-11H3/b13-12+,20-15+,24-14-,47-36?/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1
|
||||
InChIKey |
ZWBTYMGEBZUQTK-PVLSIAFMSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=135398743"></iframe>
|
||||
3D MOL is unavailable | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 847 | Topological Polar Surface Area | 209 | |
XlogP | 4.7 | Complexity | 2110 | ||
Heavy Atom Count | 61 | Rotatable Bond Count | 5 | ||
Hydrogen Bond Donor Count | 5 | Hydrogen Bond Acceptor Count | 14 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Rifabutin 150 mg capsule | Click to Show/Hide the Full List of Formulation(s): 4 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Ferric oxide red; Potassium hydroxide; Titanium dioxide; Crospovidone; Silicon dioxide; Cellulose, microcrystalline; Gelatin; Shellac
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Avera McKennan Hospital; Lupin Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Crospovidone | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Ferric oxide red; Potassium hydroxide; Titanium dioxide; Silicon dioxide; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Gelatin; Shellac
|
|||||
Dosage Form | Oral Capsule | |||||
Company | American Health Packaging | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Drug Formulation 3 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Ferric oxide red; Titanium dioxide; Silicon dioxide; Cellulose, microcrystalline
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Department of State Health Services, Pharmacy Branch; Physicians Total Care | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Drug Formulation 4 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Ferric oxide red; Titanium dioxide; Silicon dioxide; Microcrystalline cellulose
|
|||||
Dosage Form | Oral Capsule | |||||
Company | Greenstone; Pharmacia and Upjohn Company | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.